Novel signal pathway mediating Hypertension/Obesity-dependent Insulin Resistance
介导高血压/肥胖依赖性胰岛素抵抗的新信号通路
基本信息
- 批准号:8611325
- 负责人:
- 金额:$ 23.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-06-01 至 2014-05-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): The Metabolic Syndrome defines a constellation of conditions, often co-existing in an individual, that together greatly enhance the risk of developing diabetes and coronary artery disease. Two of the major components of the Metabolic Syndrome are hypertension and obesity. Since there has been a marked increase in the incidence of these conditions within the western population, it is becoming increasingly important to understand how these risk factors contribute to the onset of the costly and debilitating diseases of diabetes and heart disease. Angiotensin II (Ang II) is a peptide hormone whose overproduction is one of the most common causes of hypertension. While the effects of Ang II on blood pressure are primarily mediated through its actions on the vascular bed, the hormone also acts in a variety of other tissues. It is in these tissues, such as liver, that Ang II activates the NF-:B transcription factor, an event that is central to the development of insulin resistance. Numerous studies have shown that activation of NF-:B serves as a mechanism for inhibitory cross-talk with insulin signal transduction. We recently described a novel intracellular signaling pathway that mediates Ang II- dependent activation of NF-:B in hepatocytes, and involves the concerted efforts of three principal proteins, CARMA3, Bcl10, and MALT1. Thus, we hypothesize that this signaling pathway may be critical to the development of Ang II-dependent insulin resistance. Interestingly, free fatty acids (FFAs), which are elevated in the plasma of obese individuals, also activate hepatic NF-:B and thereby contribute to insulin resistance. Since the actions of Ang II and FFAs share a number of features, we further hypothesize that FFAs utilize the same CARMA3/Bcl10/MALT1 pathway to activate NF-:B and induce a state of insulin resistance. The goal of this grant proposal is to further test the role of CARMA3, Bcl10, and MALT1 in blocking insulin signaling in liver, and in promoting the physiologic state of insulin resistance in the setting of chronic obesity or Ang II overproduction. We will accomplish this goal through four specific aims that (1) specifically test whether FFA induction of NF-:B does in fact depend on the CARMA3/Bcl10/MALT1 pathway, (2) test the role of the CARMA3/Bcl10/MALT1 pathway in mediating cross-talk with hepatic insulin signaling pathways, (3) test the role of the CARMA3, Bcl10, and MALT1 proteins in mediating Ang II- and obesity-dependent insulin resistance in a mouse model, and (4) test if genetically deleting CARMA3 will restore a normal insulin-sensitive phenotype in a strain of mice that are prone to developing insulin resistance because of defective Leptin signaling. PUBLIC HEALTH RELEVANCE: The onset of hypertension- or obesity-dependent insulin resistance is a first major step toward the development of type 2 diabetes, a condition that is typically irreversible. It is therefore critical that we further explore the molecular mechanisms that underlie insulin resistance, with the goal of developing novel strategies for blocking the progression to diabetes. This proposal will explore a novel signaling pathway that may underlie some of the most common causes of insulin resistance and may thereby provide new molecular targets for therapeutic intervention.
描述(由申请人提供):代谢综合征定义了一系列通常在个体中共存的疾病,这些疾病共同极大地增加了发展为糖尿病和冠状动脉疾病的风险。代谢综合征的两个主要组成部分是高血压和肥胖。由于这些疾病在西方人群中的发病率显著增加,了解这些风险因素如何导致代价高昂且使人虚弱的糖尿病和心脏病的发病变得越来越重要。血管紧张素II(Ang II)是一种多肽激素,其过度分泌是高血压最常见的原因之一。虽然Ang II对血压的影响主要是通过它在血管床上的作用来调节的,但这种激素也在其他各种组织中发挥作用。正是在这些组织中,如肝脏,Ang II激活了核因子-:B转录因子,这一事件是胰岛素抵抗发展的核心。大量研究表明,核因子-B的激活是抑制胰岛素信号转导串扰的一种机制。我们最近描述了一种新的细胞内信号通路,它介导了肝细胞中Ang II依赖的NF:B的激活,涉及三个主要蛋白质CARMA3、Bcl10和MALT1的协同作用。因此,我们推测这一信号通路可能在血管紧张素Ⅱ依赖型胰岛素抵抗的发生发展中起关键作用。有趣的是,肥胖者血浆中升高的游离脂肪酸(FFAs)也会激活肝脏的核因子-B,从而导致胰岛素抵抗。由于Ang II和FFAs的作用有许多共同的特征,我们进一步假设FFAs利用相同的CARMA3/Bcl10/MALT1途径激活NF-:B并诱导胰岛素抵抗。这项拨款提案的目的是进一步测试CARMA3、Bcl10和MALT1在阻断肝脏中的胰岛素信号,以及在慢性肥胖或Ang II生产过剩的背景下促进胰岛素抵抗的生理状态中的作用。我们将通过四个具体目标来实现这一目标,这四个目标是:(1)具体测试FFA对NF-:B的诱导是否确实依赖于CARMA3/Bcl10/MALT1通路;(2)测试CARMA3/Bcl10/MALT1通路在介导与肝脏胰岛素信号通路的串扰中的作用;(3)在小鼠模型中测试CARMA3、Bcl10和MALT1蛋白在介导Ang II和肥胖依赖的胰岛素抵抗中的作用;以及(4)测试通过基因删除CARMA3是否可以恢复由于瘦素信号缺陷而容易发生胰岛素抵抗的小鼠的正常胰岛素敏感表型。公共卫生相关性:高血压或肥胖依赖型胰岛素抵抗的出现是发展成2型糖尿病的第一个重要步骤,而2型糖尿病通常是不可逆转的。因此,我们必须进一步探索胰岛素抵抗的分子机制,目标是开发阻止糖尿病进展的新策略。这项提议将探索一种新的信号通路,该通路可能是导致胰岛素抵抗的一些最常见原因的基础,从而可能为治疗干预提供新的分子靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER C LUCAS其他文献
PETER C LUCAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER C LUCAS', 18)}}的其他基金
Role of MALT1 in regulating the breast cancer immune microenvironment
MALT1在调节乳腺癌免疫微环境中的作用
- 批准号:
10656975 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
New mechanisms for modulating the MALT1 oncoprotein
调节 MALT1 癌蛋白的新机制
- 批准号:
10092117 - 财政年份:2018
- 资助金额:
$ 23.99万 - 项目类别:
New mechanisms for modulating the MALT1 oncoprotein
调节 MALT1 癌蛋白的新机制
- 批准号:
9445635 - 财政年份:2018
- 资助金额:
$ 23.99万 - 项目类别:
Novel signal pathway mediating Hypertension/Obesity-dependent Insulin Resistance
介导高血压/肥胖依赖性胰岛素抵抗的新信号通路
- 批准号:
8305801 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
A Novel Signaling Pathway Mediating Hypertension- and Obesity-dependent Insulin R
介导高血压和肥胖依赖性胰岛素 R 的新型信号通路
- 批准号:
7649758 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
Novel signal pathway mediating Hypertension/Obesity-dependent Insulin Resistance
介导高血压/肥胖依赖性胰岛素抵抗的新信号通路
- 批准号:
8081071 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
A Novel Signaling Pathway Mediating Hypertension- and Obesity-dependent Insulin R
介导高血压和肥胖依赖性胰岛素 R 的新型信号通路
- 批准号:
7846142 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
Novel signal pathway mediating Hypertension/Obesity-dependent Insulin Resistance
介导高血压/肥胖依赖性胰岛素抵抗的新信号通路
- 批准号:
8478086 - 财政年份:2009
- 资助金额:
$ 23.99万 - 项目类别:
Angiotensin II Signaling Through A Novel NF-kB Pathway
通过新型 NF-kB 通路的血管紧张素 II 信号传导
- 批准号:
7780019 - 财政年份:2008
- 资助金额:
$ 23.99万 - 项目类别:
Angiotensin II Signaling Through A Novel NF-kB Pathway
通过新型 NF-kB 通路的血管紧张素 II 信号传导
- 批准号:
8220814 - 财政年份:2008
- 资助金额:
$ 23.99万 - 项目类别:
相似国自然基金
基于知识-数据驱动的快速路多车道车速-车距非均匀分布下交通流建模研究
- 批准号:2025JJ50457
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
组蛋白乙酰化修饰ATG13激活自噬在牵张应力介导骨缝Gli1+干细胞成骨中的机制研究
- 批准号:82370988
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
胰岛素和细菌信号协同调节巨噬细胞免疫反应的作用
- 批准号:92057105
- 批准年份:2020
- 资助金额:89.0 万元
- 项目类别:重大研究计划
谷氨酰胺缺失引发的线粒体融合调控肿瘤细胞代谢稳态的机制研究
- 批准号:31900542
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
一种新的质子感知Gq蛋白偶联受体的筛选及其鉴定
- 批准号:31960149
- 批准年份:2019
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
钙信号负向调节因子IRBIT抑制肝癌细胞恶性生物学行为的分子机制研究
- 批准号:31960151
- 批准年份:2019
- 资助金额:40.0 万元
- 项目类别:地区科学基金项目
内质网–质膜互作在凋亡细胞磷脂酰丝氨酸外翻过程中的作用机制研究
- 批准号:91954114
- 批准年份:2019
- 资助金额:76.0 万元
- 项目类别:重大研究计划
基于钙信号特征机制的肿瘤转移调控研究
- 批准号:31970729
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
GRK2-GPR161协同调控Hh通路信号传递分子机制的研究
- 批准号:31970738
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
Smurf1介导的p120-catenin单泛素化修饰在上皮间质转化及肿瘤扩散过程中的作用和分子机制的研究
- 批准号:31970742
- 批准年份:2019
- 资助金额:58.0 万元
- 项目类别:面上项目
相似海外基金
Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex
检查心脏连接膜复合体中新型蛋白质的功能
- 批准号:
10749672 - 财政年份:2024
- 资助金额:
$ 23.99万 - 项目类别:
The Role of Astrocyte Elevated Gene-1 (AEG-1), A Novel Multifunctional Protein, In Chemotherapy-Induced Peripheral Neuropathy
星形胶质细胞升高基因 1 (AEG-1)(一种新型多功能蛋白)在化疗引起的周围神经病变中的作用
- 批准号:
10679708 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
Novel mechanisms of microRNA-mediated anabolic effects in age-related osteoarthritis
microRNA介导的年龄相关骨关节炎合成代谢作用的新机制
- 批准号:
10663670 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
A Novel VpreB1 Anti-body Drug Conjugate for the Treatment of B-Lineage Acute Lymphoblastic Leukemia/Lymphoma
一种用于治疗 B 系急性淋巴细胞白血病/淋巴瘤的新型 VpreB1 抗体药物偶联物
- 批准号:
10651082 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
Evaluating a novel, orally-active TREM2-targeting drug in AD
评估一种新型口服活性 TREM2 靶向药物治疗 AD 的效果
- 批准号:
10735206 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
Advancing BITT-101 a novel dominant CD40 antagonist for use in treatment of Sjogren Syndrome.
推进 BITT-101 成为一种新型 CD40 拮抗剂,用于治疗干燥综合征。
- 批准号:
10760568 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
Identifying and targeting a novel mechanism of chemotherapy-induced immunotherapeutic resistance in non-small cell lung cancer
识别和靶向非小细胞肺癌化疗引起的免疫治疗耐药的新机制
- 批准号:
10657188 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:
LRP1 as a novel regulator of CXCR4 in adult neural stem cells and post-stroke response
LRP1 作为成体神经干细胞和中风后反应中 CXCR4 的新型调节剂
- 批准号:
10701231 - 财政年份:2023
- 资助金额:
$ 23.99万 - 项目类别:














{{item.name}}会员




